Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Shares of Bausch Health Companies Inc. BHC gained 2.36% after the company reported better-than-expected fourth-quarter ...

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated ...

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated ...

With increasing interest in developing antifibrotic therapies, there is a need for cell lines that preserve the in vivo phenotype of human HSCs to elucidate pathways of human hepatic fibrosis. We ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Xifaxan ® drove sales in the fourth quarter with 16% growth and was the primary contributor to segment growth for the full year. International segment reported revenues were $279 million for the ...

Bausch Health Companies Inc. announces strong Q4 and full-year 2024 financial results, achieving revenue growth in all segments and exceeding adjusted EBITDA guidance ...